Document Detail

Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.
MedLine Citation:
PMID:  21212528     Owner:  NLM     Status:  In-Process    
Intracellular concentration of imatinib in leukemic cells is thought to affect the clinical efficacy of this drug in patients with chronic myeloid leukemia (CML); however, there is no report that directly indicates the relationship between intracellular concentration and clinical outcome and/or, plasma concentration. In addition, the impacts of genetic variations of drug transporters, which mediate leukocyte concentration of imatinib, are unknown. In the present study, we investigated the correlation between intracellular imatinib concentrations in leukocytes, plasma imatinib levels, and genotypes of drug transporters, including ATP binding cassette B1 (ABCB), ABCG2, solute carrier 22A1 (SLC22A1), solute carrier organic anion transporter family members 1B1 (SLCO1B1) and SLCO1B3. The imatinib levels in leukocytes were determined using HPLC in 15 patients with chronic phase CML. No significant correlation between intracellular and plasma concentrations of imatinib was observed. The intracellular concentration was comparable in both patients with or without complete cytogenetic response. The intracellular imatinib concentration was significantly higher in patients with SLCO1B3 334TT than in those with 334TG/GG (p=0.0188). Plasma concentrations were similar in both SLCO1B3 genotypes (p=0.860), thereby resulting in the intracellular to plasma concentration ratio being higher in patients with SLCO1B3 334TT than those with 334 TG/GG (p=0.0502). These results suggested that the SLCO1B3 334T>G polymorphism could have a significant impact on the intracellular concentration of imatinib in leukocytes as a promising biomarker for personalized treatment of CML patients.
Takeru Nambu; Akinobu Hamada; Reiko Nakashima; Misato Yuki; Tatsuya Kawaguchi; Hiroaki Mitsuya; Hideyuki Saito
Related Documents :
21544918 - Fetal adrenal development: comparing effects of combined exposures to pcb 118 and pcb 1...
6880858 - The diagnostic value of determination of intraerythrocytic sodium and potassium concent...
11881568 - Membrane na+ k+ atpase inhibition related dyslipidemia and insulin resistance in neurop...
277128 - Pharmacokinetics of dextropropoxyphene in acute poisoning.
14994788 - Evaluation of three concentrations of tebufenpyrad for the control of varroa destructor...
1325608 - Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of cushin...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biological & pharmaceutical bulletin     Volume:  34     ISSN:  1347-5215     ISO Abbreviation:  Biol. Pharm. Bull.     Publication Date:  2011  
Date Detail:
Created Date:  2011-01-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9311984     Medline TA:  Biol Pharm Bull     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  114-9     Citation Subset:  IM    
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epile...
Next Document:  Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypert...